ClinicalTrials.gg
Active, not recruitingNCT06026254Updated Nov 18, 2024

A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

A Phase 1 interventional study of IMSA101 and Immune Checkpoint Inhibitor in Solid Tumor, Adult, sponsored by ImmuneSensor Therapeutics Inc.. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-18.

Sponsored by ImmuneSensor Therapeutics Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).

Read the detailed description

The following methodology applies to all patients:

  • Treatment cycles will be 28 days in duration with lesions injected every 2 weeks. IMSA101 dose level will remain the same as at the time of the rollover from parent protocol.
  • ICI dose level and treatment regimen will remain the same as at the time of the rollover from parent protocol, following the labeled instructions.
  • The same single pre-defined lesion/lesion site (longest diameter ≥ 10 mm and ≤ 50 mm) shall be injected throughout study duration, if possible. Where the original injection site is considered by the investigator to become inaccessible, a second lesion/lesion site shall be selected as a replacement and this shall be used henceforth so long as it is considered accessible. Subsequent injection sites shall be replaced when they are considered inaccessible.
  • Where no remaining accessible lesions are present and where benefit of IMSA101 therapy is, in the opinion of the investigator, being derived by the patient, continued injections of IMSA101 into the vicinity of an inaccessible lesion or, in the case that a lesion can no longer be radiographically visualized, into the last known location of the non-visible lesion shall be allowed.
02

Conditions studied

  • Solid Tumor, Adult
03

In context

Lead sponsor

ImmuneSensor Therapeutics Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and mental capability to understand the informed consent
  2. Currently enrolled in parent protocol IMSA101-101 and is receiving IMSA101 treatment
  3. Deriving clinical benefit from study treatment, as determined by the investigator
  4. Must have fulfilled all required assessments in parent protocol IMSA101-101
  5. Male and female patients with must agree to use two forms of highly effective throughout the study

Exclusion criteria

Exclusion Criteria:

  1. Permanently discontinued from IMSA101 treatment in parent protocol IMSA101-101 for any reason other than enrollment in the rollover study
  2. Failure to meet the criteria specified in parent protocol IMSA101-101 for continued study treatment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (estimated)

Study arms

  • Experimental
    Combination Therapy

    IMSA101 + ICI

    Drug: IMSA101 · Drug: Immune Checkpoint Inhibitor

Interventions

06

What researchers measure

Primary outcomes

  1. Drug-related safety

    Frequency of drug-related SAE by subject

    Time frame: 12 months

  2. Anti-tumor effects

    Tumor response based on RECIST v1.1

    Time frame: 12 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Sep 2025, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2023
First posted
Sep 7, 2023
StartActual
Sep 15, 2023
Primary completionEst.
Sep 2025
CompletionEst.
Sep 2025
Last update
Nov 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06026254
Lead sponsor
ImmuneSensor Therapeutics Inc.
Responsible party
Sponsor
First posted
Sep 7, 2023
Start date
Sep 15, 2023
Primary completion
Sep 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Nov 18, 2024

Study contacts

Teresa Mooneyham
study chair · ImmuneSensor Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STING Agonist IMSA101

Start the discussion